Merck KGaA Company Profile (NASDAQ:MKGAY)

About Merck KGaA (NASDAQ:MKGAY)

Merck KGaA logoMerck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin. The Consumer Health division comprises the over-the-counter products for preventive health care and self-treatment of minor ailments. The Merck Serono and Consumer Health divisions form together the Company's Pharmaceutical business sector. The Merck Millipore division comprises the activities of the Millipore Corporation. The Performance Materials division consists mainly of the Liquid Crystals and Pigments & Cosmetics business units. The Company operates through numerous subsidiaries, including Peer+ BV, AZ Electronic Materials (AZ), BioControl Systems Inc and Ormet Circuits Inc., a material supplier for the semiconductor industry.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MKGAY
  • CUSIP: N/A
  • Web: www.emdgroup.com/
Average Prices:
  • 50 Day Moving Avg: $39.80
  • 200 Day Moving Avg: $38.15
  • 52 Week Range: $32.53 - $42.02
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 5.57
  • P/E Growth: 0.00
Dividend:
  • Dividend Yield: 1.1%
Misc:
  • Average Volume: 6,879 shs.
 

Frequently Asked Questions for Merck KGaA (NASDAQ:MKGAY)

What is Merck KGaA's stock symbol?

Merck KGaA trades on the NASDAQ under the ticker symbol "MKGAY."

Who are some of Merck KGaA's key competitors?

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the folowing people:

  • Wolfgang Buechele, Chairman of the Supervisory Board
  • Stefan Oschmann Ph.D., Chairman of Executive Board and Chief Executive Officer
  • Michael Fletterich, Vice Chairman of the Supervisory Board, Employee Representative
  • Marcus Kuhnert, Member of the Executive Board, Chief Financial Officer
  • Udit Batra, CEO Life Science, Member of the Executive Board
  • Walter Heinrich Galinat, CEO Performance Materials, Member of the Executive Board
  • Belen Garijo, CEO Healthcare, Member of the Executive Board
  • Kai Beckmann, Chief Administrative Officer, Member of the Executive Board
  • Constantin Fest, Head of Investor Relations
  • Constantin Birnstiel, Head of Group Communications

How do I buy Merck KGaA stock?

Shares of Merck KGaA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck KGaA's stock price today?

One share of Merck KGaA stock can currently be purchased for approximately $38.36.


MarketBeat Community Rating for Merck KGaA (NASDAQ MKGAY)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  222
MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Merck KGaA (NASDAQ:MKGAY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating
Consensus Rating:Hold (Score: 1.50)
Consensus Price Target: N/A
Consensus Price Target History for Merck KGaA (NASDAQ:MKGAY)
Price Target History for Merck KGaA (NASDAQ:MKGAY)
Analysts' Ratings History for Merck KGaA (NASDAQ:MKGAY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/26/2017Deutsche Bank AGReiterated RatingBuy -> HoldLowView Rating Details
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
10/14/2016Bank of America CorporationUpgradeNeutral -> BuyN/AView Rating Details
8/12/2016Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
8/10/2016Credit Suisse GroupUpgradeNeutral -> Outperform$73.00N/AView Rating Details
8/10/2016Jefferies Group LLCReiterated RatingHold$53.00 -> $57.00N/AView Rating Details
7/18/2016BMO Capital MarketsReiterated RatingMarket PerformN/AView Rating Details
5/25/2016DZ Bank AGReiterated RatingBuyN/AView Rating Details
5/19/2016J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
5/17/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
4/8/2016Nord/LBReiterated RatingBuyN/AView Rating Details
2/6/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$60.00 -> $56.00N/AView Rating Details
12/1/2015Barclays PLCUpgradeEqual Weight -> Overweight$64.00 -> $66.00N/AView Rating Details
11/17/2015ArgusReiterated RatingBuy$70.00 -> $65.00N/AView Rating Details
10/26/2015Societe GeneraleReiterated RatingNeutralN/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Merck KGaA (NASDAQ:MKGAY)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Merck KGaA (NASDAQ:MKGAY)
Current Year EPS Consensus Estimate: $6.99 EPS
Next Year EPS Consensus Estimate: $6.89 EPS

Dividends

Dividend History for Merck KGaA (NASDAQ:MKGAY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Merck KGaA (NASDAQ:MKGAY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Merck KGaA (NASDAQ:MKGAY)
Latest Headlines for Merck KGaA (NASDAQ:MKGAY)
Source:
DateHeadline
seekingalpha.com logoPfizer and Merck KGaA's Bavencio OK'd in Japan for rare skin cancer
seekingalpha.com - September 27 at 9:36 AM
seekingalpha.com logoMerck KGaA mulling sale of consumer health unit
seekingalpha.com - September 5 at 9:31 PM
feeds.benzinga.com logoBiocartis Group NV: Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO
feeds.benzinga.com - August 31 at 2:08 AM
seekingalpha.com logoMerck KGaA acquires chromatography membrane maker Natrix Separations
seekingalpha.com - August 28 at 1:16 PM
rttnews.com logoMerck KGaA Says NICE Issues Positive FAD Recommending Routine NHS Use Of Erbitux
www.rttnews.com - August 9 at 12:14 AM
nasdaq.com logoMerck KgaA Q2 Profit Climbs, Maintains FY17 Earnings Forecast; Trims Sales View
www.nasdaq.com - August 3 at 5:26 AM
americanbankingnews.com logoMerck KGaA (NASDAQ:MKGAY) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 26 at 11:06 AM
americanbankingnews.com logoDeutsche Bank AG Downgrades Merck KGaA (MKGAY) to Hold
www.americanbankingnews.com - July 26 at 9:39 AM
rttnews.com logoMerck KgaA' Cladribine Tablets Gets Positive CHMP Opinion For Treatment Of RMS
www.rttnews.com - June 24 at 6:59 PM
rttnews.com logoMerck KGaA Ventures Forms New Immuno-Oncology Company IOnctura
www.rttnews.com - June 21 at 12:38 AM
seekingalpha.com logoGerman Merck Doubles Down On Dual-Acting Cancer Agents
seekingalpha.com - June 13 at 6:41 PM
seekingalpha.com logoMerck Reveals Its Gastric Cancer Hand
seekingalpha.com - June 6 at 7:16 PM
nasdaq.com logoMerck KgaA Q1 Profit Down, Sales Rise; Backs FY17 Organic Sales Growth View
www.nasdaq.com - May 19 at 11:06 AM
nasdaq.com logoMerck KgaA Q1 Profit Dips, Adj. EBITDA Rises; Backs FY17 Sales Growth View
www.nasdaq.com - May 18 at 8:32 AM
rttnews.com logoMerck KGaA Plans Measures For Structural Development Of Its Business Sectors
www.rttnews.com - May 17 at 6:30 PM
seekingalpha.com logoTurmoil In Immuno-Oncology
seekingalpha.com - May 15 at 10:25 AM
seekingalpha.com logoKeytruda Gets Hot And Propels Merck: Analysis
seekingalpha.com - May 11 at 7:04 PM
nasdaq.com logoPfizer : FDA Grants BAVENCIO Approval For Common Type Of Advanced Bladder Cancer
www.nasdaq.com - May 10 at 12:28 PM
rttnews.com logoMerck KGaA : EC Grants Approval For New Pergoveris Pen For Fertility Treatment
www.rttnews.com - May 10 at 12:28 PM
rttnews.com logoMerck Raises Dividend
www.rttnews.com - April 28 at 7:29 PM
seekingalpha.com logoFresenius Shows Biotech How To Get The Deals Done
seekingalpha.com - April 26 at 11:44 PM
seekingalpha.com logoBeiGene, Another Beijing Venture In Cancer Therapy
seekingalpha.com - March 25 at 6:13 PM
rttnews.com logoMerck KGaA : FDA Approves First Treatment For Rare Form Of Skin Cancer
www.rttnews.com - March 24 at 12:08 AM
seekingalpha.com logoFDA OKs Merck KGaA and Pfizer's avelumab for rare type of skin cancer
seekingalpha.com - March 23 at 7:06 PM
seekingalpha.com logoPfizer And Merck Go For An Even Longer Throw Of The Javelin
seekingalpha.com - March 11 at 12:52 AM
nasdaq.com logoMerck KgaA Q4 Profit More Than Doubles; Proposes Higher Dividend
www.nasdaq.com - March 9 at 8:44 AM
rttnews.com logoMerck KgaA Q4 Profit Soars, Sees Stable Earnings In FY17; Stock Dips
www.rttnews.com - March 9 at 8:44 AM
seekingalpha.com logoFDA accepts EMD Serono's BLA for avelumab for urothelial carcinoma; action date August 27
seekingalpha.com - February 28 at 6:41 PM
seekingalpha.com logoMerck KGaA teams up with Domain Therapeutics in immuno-oncology
seekingalpha.com - January 23 at 10:10 AM
seekingalpha.com logoAstra's Mystic Mystery And Other Surprises In Store
seekingalpha.com - January 18 at 7:05 PM
rttnews.com logoMerck KGaA And Palantir Launch New Healthcare Acceleration Partnership
www.rttnews.com - January 13 at 5:07 AM
seekingalpha.com logoVertex to collaborate with Germany's Merck in oncology
seekingalpha.com - January 12 at 12:10 AM
seekingalpha.com logoGerman Merck Unveils Its Secret Weapon
seekingalpha.com - January 10 at 7:27 PM
publicnow.com logoMerck Acquires BioControl to Strengthen Position in Food Safety Testing
us.rd.yahoo.com - January 4 at 7:23 PM
rttnews.com logoMerck KGaA Acquires BioControl Systems
www.rttnews.com - January 4 at 7:23 PM
rttnews.com logoRoche Expands Distribution Agreement With Merck KgaA's Life Science Business
www.rttnews.com - December 1 at 9:37 AM
seekingalpha.com logoRoche expands distribution partnership with Merck KGaA
seekingalpha.com - December 1 at 9:37 AM
seekingalpha.com logoEvotec and Merck KGaA team up to discover new therapeutic targets
seekingalpha.com - November 30 at 11:21 AM
us.rd.yahoo.com logo8:19 am Merck KGaA and Pfizer (PFE) announce that the FDA has accepted for Priority Review MKGAY's BLA for avelumab
us.rd.yahoo.com - November 29 at 2:51 PM
seekingalpha.com logoFDA accepts avelumab BLA under Priority Review for rare type of skin cancer
seekingalpha.com - November 29 at 2:51 PM
seekingalpha.com logoQuintilesIMS forms collaboration with major drug firms to better understand real-world uses of cancer treatments
seekingalpha.com - November 22 at 10:21 AM
msn.com logoGermany's Merck Lifts Full Year Guidance After Sigma-Aldrich Boosts Sales
www.msn.com - November 16 at 9:51 AM
rttnews.com logoMerck KgaA Lifts FY16 Earnings View As Q3 Results Climb, Stock Up
www.rttnews.com - November 15 at 9:52 AM
seekingalpha.com logoTransgene Pins Hopes On Cancer Vaccine Combos
seekingalpha.com - October 14 at 5:58 PM
rttnews.com logoMerck KgaA To Meet 2018 Targets; Sees EUR 4 Bln Sales From New Products By 2022
www.rttnews.com - October 13 at 9:44 AM
rttnews.com logoMerck KGaA Invests Over €50 Mln In Pharma Packaging Building In Darmstadt
www.rttnews.com - September 21 at 10:17 AM

Social

Chart

Merck KGaA (MKGAY) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.